Legal & General Group Plc lifted its stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 3.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,239 shares of the biotechnology company’s stock after purchasing an additional 1,074 shares during the period. Legal & General Group Plc’s holdings in Sarepta Therapeutics were worth $4,723,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of SRPT. TIAA CREF Investment Management LLC lifted its holdings in Sarepta Therapeutics by 35.5% during the third quarter. TIAA CREF Investment Management LLC now owns 281,890 shares of the biotechnology company’s stock worth $45,528,000 after acquiring an additional 73,792 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Sarepta Therapeutics by 41.6% in the 3rd quarter. Teachers Advisors LLC now owns 132,916 shares of the biotechnology company’s stock valued at $21,467,000 after purchasing an additional 39,036 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at about $3,715,000. Macquarie Group Ltd. raised its stake in shares of Sarepta Therapeutics by 34.4% in the 3rd quarter. Macquarie Group Ltd. now owns 514,952 shares of the biotechnology company’s stock valued at $83,170,000 after purchasing an additional 131,859 shares during the period. Finally, Mackenzie Financial Corp acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at about $574,000. Institutional investors and hedge funds own 90.85% of the company’s stock.
Several analysts have issued reports on SRPT shares. HC Wainwright reissued a “buy” rating and issued a $267.00 price target on shares of Sarepta Therapeutics in a research note on Friday, September 21st. BidaskClub downgraded Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 22nd. Needham & Company LLC dropped their price target on Sarepta Therapeutics to $196.00 and set a “buy” rating on the stock in a research note on Monday, September 24th. BTIG Research set a $190.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Monday, September 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $200.00 price target (up previously from $187.00) on shares of Sarepta Therapeutics in a research note on Wednesday, September 26th. Four analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has issued a strong buy rating to the stock. Sarepta Therapeutics has an average rating of “Buy” and a consensus target price of $182.50.
NASDAQ:SRPT opened at $120.57 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 7.84 and a current ratio of 8.85. The stock has a market capitalization of $7.68 billion, a P/E ratio of -73.52 and a beta of 1.91. Sarepta Therapeutics Inc has a 52-week low of $50.68 and a 52-week high of $176.50.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.29). The company had revenue of $78.49 million during the quarter, compared to analyst estimates of $78.84 million. Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 23.67%. On average, analysts anticipate that Sarepta Therapeutics Inc will post -4.37 earnings per share for the current year.
In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $140.50, for a total transaction of $936,713.50. Following the transaction, the director now owns 126,534 shares of the company’s stock, valued at $17,778,027. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Sandesh Mahatme sold 107,524 shares of the business’s stock in a transaction that occurred on Wednesday, October 24th. The stock was sold at an average price of $127.74, for a total value of $13,735,115.76. Following the transaction, the chief financial officer now directly owns 48,381 shares in the company, valued at approximately $6,180,188.94. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by insiders.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Recommended Story: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.